Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Smith & Nephew plc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $32.31, while Smith & Nephew plc trades at $29.8 (market cap $12.54B). The key difference: Smith & Nephew plc pays a 2.65% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| FNGU | SNN | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $36.15 | $38.70 |
52-Week Low | $13.73 | $28.73 |
Market Cap | — | $12.54B |
Enterprise Value | — | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU (MicroSectors FANG+ 3X Leveraged ETN) trades at $32.45, down 3.71% today, reflecting the inherent volatility of leveraged products. Technical indicators show a bullish moving average trend but neutral oscillators, with RSI levels suggesting overbought conditions. Recent news highlights significant downside volatility, including a 16% single-session drop on June 5, 2026, underscoring the risks of 3x leverage on tech stocks.
The outlook for FNGU remains highly speculative, driven by Nasdaq-100 volatility rather than company fundamentals. Investment opportunities exist for aggressive traders betting on tech rallies, but risks include amplified losses during market downturns and structural decay from daily rebalancing. Caution is warranted given the product's design for short-term trading.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
